Dunhill Financial’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$53.7K Sell
424
-3
-0.7% -$395 0.01% 316
2026
Q1
$59.6K Sell
427
-595
-58% -$83.3K 0.01% 288
2025
Q4
$125K Buy
1,022
+15
+1% +$1.82K 0.03% 175
2025
Q3
$112K Buy
1,007
+96
+11% +$10.9K 0.03% 176
2025
Q2
$101K Sell
911
-119
-12% -$12.7K 0.03% 166
2025
Q1
$115K Buy
1,030
+91
+10% +$9.39K 0.05% 125
2024
Q4
$86.7K Buy
939
+69
+8% +$6.21K 0.04% 139
2024
Q3
$73K Buy
870
+137
+19% +$10.5K 0.04% 139
2024
Q2
$50.3K Buy
733
+26
+4% +$1.74K 0.03% 149
2024
Q1
$51.8K Buy
707
+17
+2% +$1.31K 0.04% 110
2023
Q4
$55.9K Buy
+690
New +$53.7K 0.05% 90

Other funds holding GILD

Dunhill Financial's GILD Position: Q2 2026 in Review

Dunhill Financial reduced its Gilead Sciences (GILD) stake by 0.7% in Q2 2026, selling an estimated $395 and leaving 424 shares worth $53.7K. The position accounts for 0.01% of the portfolio, ranked #316.

Dunhill Financial first reported a position in GILD in Q4 2023 and has held it in 11 quarters since. The position peaked at $125K in Q4 2025. 2,284 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Dunhill Financial held 424 shares of Gilead Sciences worth $53.7K as of Q2 2026.
  • Dunhill Financial sold 3 Gilead Sciences shares in Q2 2026, an estimated $395.
  • Gilead Sciences made up 0.01% of Dunhill Financial's portfolio in Q2 2026, its #316 holding.
  • Dunhill Financial first reported a position in Gilead Sciences in Q4 2023 and has held it in 11 quarters since.
  • Dunhill Financial's Gilead Sciences position peaked at $125K in Q4 2025.
  • 2,284 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.